Crossmark

Working to improve the management of sarcoma patients across Europe: a policy checklist

Crossref DOI link: https://doi.org/10.1186/s12885-018-4320-y

Published Online: 2018-04-16

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kasper, Bernd

Lecointe-Artzner, Estelle

Wait, Suzanne

Boldon, Shannon

Wilson, Roger

Gronchi, Alessandro

Valverde, Claudia

Eriksson, Mikael

Dumont, Sarah

Drove, Nora

Kanli, Athanasia

Wartenberg, Markus
Funding

Funding for this research was provided by:

Eli Lilly and Company
License Information

Text and Data Mining valid from 2018-04-16
More Information

Article History

Received: 29 November 2017

Accepted: 29 March 2018

First Online: 16 April 2018

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: BK, EL-A, RW, AG, CV, ME, SD and MW declare no competing interests. ND and AK are employed by Eli Lilly & Company, which provided financial support for the development of the Sarcoma Policy Checklist and this manuscript. SW and SB, from The Health Policy Partnership, provided research and writing support for this project, and The Health Policy Partnership was paid for this role. This paper, and all Sarcoma Policy Checklist publications, reflect consensus of all the experts, who hold full editorial control. All drafts of the manuscript were viewed, and approved, by all authors cited on this manuscript.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.